BioArctic's Nomination Committee appointed
BioArctic (BIOA B) has appointed its Nomination Committee to prepare proposals for the company's 2027 Annual General Meeting.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BioArctic (BIOA B) has appointed its Nomination Committee to prepare proposals for the company's 2027 Annual General Meeting.
The committee comprises Margareta Öhrvall, appointed by Demban; Pär Gellerfors, appointed by Ackelsta; and chair Thomas Ehlin, representing Fjärde AP-fonden. The Board Chair serves as convener. The represented shareholders held approximately 57 percent of shares and 82 percent of votes as of September 30, 2026. The annual meeting will take place in Stockholm on May 27, 2027, at 4.30 pm CEST. Committee proposals will appear in the meeting notice and on the company's website.
Key Figures
- Shares represented
- Approximately 57%
- Shares held by shareholders represented on the Nomination Committee
- Voting rights represented
- 82%
- Votes held by shareholders represented on the Nomination Committee
- Proposal submission deadline
- January 15, 2027
- Deadline for proposals to the Nomination Committee
- Annual General Meeting
- May 27, 2027
- Scheduled meeting date
- Matter submission deadline
- April 15, 2027
- Deadline for a matter to be included in the AGM notice
AI-generated analysis. How Rhea-AI works. Not financial advice.
The Nomination Committee has been appointed in accordance with the principles adopted by the Annual General Meeting and consists of representatives of the three largest shareholders by voting rights as of September 30, 2026, as well as the Chair of the Board (convener).
The Nomination Committee comprises the following members:
- Margareta Öhrvall, appointed by Demban AB
- Pär Gellerfors, appointed by Ackelsta AB
- Thomas Ehlin, Chair of the Nomination Committee, representing Fjärde AP-fonden
As of September 30, 2026, the shareholders represented on the Nomination Committee together hold approximately 57 percent of the shares and 82 percent of the votes in the Company.
The instruction for the Nomination Committee is available on BioArctic's website www.bioarctic.com/en/governance/nomination-committee/
The Nomination Committee's proposals will be presented in the notice to the Annual General Meeting 2027, as well as on the company's website, www.bioarctic.com
Shareholders wishing to submit proposals to the Nomination Committee may do so by e-mail to ir@bioarctic.com (please mark the e-mail "Nomination Committee") or by post to BioArctic AB, Att: Nomination Committee, Warfvinges väg 35, SE-112 51
BioArctic's Annual General Meeting 2027 will be held on Thursday, May 27, 2027, at 4.30 pm CEST in
The information was released for public disclosure, through the agency of the contact person below, on October 30, 2026, at 3 pm CET.
For further information, please contact:
Oskar Bosson, Chief Investor Relations & Communications Officer
E-mail: oskar.bosson@bioarctic.com
Telephone: +46 704 107 180
Jenny Ljunggren, External Communications and Investor Relations Manager
E-mail: jenny.ljunggren@bioarctic.com
Telephone: +46 76 013 86 08
About BioArctic AB
BioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company invented Leqembi® (lecanemab) – the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with BioArctic's partner Eisai, who are responsible for regulatory interactions and commercialization globally. In addition to Leqembi, BioArctic has a broad research portfolio with antibodies against Parkinson's-related diseases and ALS as well as additional projects against Alzheimer's disease. Several of the projects utilize the company's proprietary BrainTransporter™ technology, which has the potential to actively transport therapies across the blood-brain barrier to enhance the efficacy of the treatment. BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For further information, please visit www.bioarctic.com.
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/bioarctic/r/bioarctic-s-nomination-committee-appointed,c4417898
The following files are available for download:
|
​​​​​​​BioArctic’s Nomination Committee appointed |
View original content:https://www.prnewswire.com/news-releases/bioarctics-nomination-committee-appointed-302925013.html
SOURCE BioArctic
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.